Loading clinical trials...
Loading clinical trials...
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or folli...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hoffmann-La Roche
NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more
NCT05672251 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, and more
NCT07200375 · Diffuse Large B-Cell Lymphoma
NCT06249191 · Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
NCT03223610 · Lymphoma, Non-Hodgkin Lymphoma, and more
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing
the First Hospital of Jilin University
Changchun
Xiangya Hospital of Centre-South University
Changsha
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions